Navigation Links
Biotechnology Pharmaceutical Company Selects NewCardio's QTinno for Thorough QT Trial
Date:1/11/2012

PRINCETON, N.J., Jan. 11, 2012 /PRNewswire/ -- NewCardio, Inc., (OTC BB: NWCI) a cardiovascular diagnostic solutions developer, announced today that a biotechnology pharmaceutical company, which is focused on discovering and developing small molecule therapeutics for disorders of the central nervous system (CNS), has selected QTinno®, NewCardio's automated cardiac safety solution, for an upcoming Thorough QT trial. Fully automated ECG analysis, empowered by QTinno, will be delivered by the ECG core lab of a top 3 Clinical Research Organization (CRO) under the terms of an existing Master Services Agreement with NewCardio.    

The current study timeline anticipates initiating the study in January, with completion in the April timeframe. QTinno was selected, and specifically written into the protocol by the drug development sponsor, based on its proven ability to enable the CRO to deliver high-quality results in a much more timely and cost effective manner than the current core ECG lab methodologies. It is anticipated that the study will generate approximately $250,000 in revenue for NewCardio.

Greg Sadowski, NewCardio's Chief Operating Officer, commented, "We are excited to participate in this TQT trial for an emerging biotech with our CRO partner. QTinno's selection for this study, based on the performance in prior studies, provides clear evidence of the pharmaceutical company's confidence, not only in the accuracy and precision of QTinno's fully automated ECG analysis, but also in the FDA's willingness to accept drug safety data from properly validated technology such as QTinno." 

About QTinno Technology

NewCardio's patented QTinno 3-D ECG software technology is a novel, fully automated program for evaluating QT and other timing intervals relevant for assessing drug cardiac toxicity in drug development. It provides fast, accurate and precise QT data from a broad range of challenging ECGs and enables rel
'/>"/>

SOURCE NewCardio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
2. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
3. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
4. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
5. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
6. Genetic Engineering & Biotechnology News Reports on the Growing Role of Ion-Channel Studies in Global Biotech R&D
7. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
8. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
9. Dr. Ari Kiev to be Featured Speaker at Biotechnology Conference Wall Street Unplugged: The Trout Group Investor Seminar in New York July 30
10. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
11. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
(Date:1/14/2014)... HARRISBURG, Pa. , Jan. 14, 2014 Dynamic Healthcare ... ("GMH"), announced today that it acquired Progressive Home Medical Equipment, ... January 7, 2014. The terms of the acquisition were not ... medical equipment ("DME") company providing a wide range of sleep, ...
(Date:1/14/2014)... 2014 NineSigma , Inc., the leading innovation ... Leadership Summit , May 14-16, 2014 at the Global ... . This is the premier ... breakthrough achievements through open innovation. Participants will learn how ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... 2011 Varian Medical Systems (NYSE: VAR ... information system has received Surescripts® e-prescribing certification for new ... ARIA system to manage radiation therapy treatments will be ... the Surescripts network. "E-Prescribing allows the ...
... Mont., May 5, 2011 Bacterin International Holdings, ... a creator and developer of revolutionary bone graft material ... it is commencing distribution of the Company,s third human ... Bacterin,s hMatrix® is an acellular matrix processed ...
Cached Medicine Technology:The ARIA® for Radiation Oncology Information System from Varian Medical Systems Now Certified by Surescripts® for E-Prescribing 2The ARIA® for Radiation Oncology Information System from Varian Medical Systems Now Certified by Surescripts® for E-Prescribing 3Bacterin International Holdings Launches Third Biologic Scaffold 2Bacterin International Holdings Launches Third Biologic Scaffold 3
(Date:4/17/2014)... of the most popular vaccine brands for children may ... be overlooking some cost factors when choosing vaccines, driving ... option, according to a new study by University of ... can be driven by numerous factors," says Sheldon H. ... of computer science and of mathematics at the U. ...
(Date:4/17/2014)... AURORA, Colo. (April 17, 2014) Two recent ... Medicine researcher and colleagues may help scientists develop ... virus, Yellow fever, Japanese encephalitis and other disease-causing ... of biochemistry and molecular genetics at the School ... the Howard Hughes Medical Institute, and colleagues recently ...
(Date:4/17/2014)... 2014U.S. military personnel who served in Iraq and ... brain injury (TBI) were compared to military personnel ... reasons. Differences in measures of overall disability, cognitive ... injury are reported in an article in ... Mary Ann Liebert, Inc., publishers. The article is ...
(Date:4/17/2014)... 2014-- Colic affects about one in five infants in ... visits during the first several months after birth. Research ... showing promise; however, the April 1, 2014 issue of ... reported on a study, "Probiotics and Infant Colic," concluding ... for infant colic did not reduce crying ...
(Date:4/17/2014)... international team led by researchers at UC Davis has ... a key role in cell division, also boosts the ... first time the complex has been shown to perform ... an excellent target to control cellular energy production, potentially ... published online today in the journal Developmental Cell ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Dual role: Key cell division proteins also power up mitochondria 2
... other particles tracked indoors can be harmful, researchers warn , ... that coats your furniture and floors comes from outdoors and ... The researchers developed a computer model that can track the ... found that more than 60 percent of household dust originates ...
... ... featured Keynote at this year,s Molecular Medicine Tri-Conference, is the inspiration for a new ... ... 11, 2009 -- Cambridge Healthtech Institute,s (CHI) flagship event, the Molecular Medicine Tri-Conference (February ...
... WellPoint,s affiliated Life and Disability Companies are pleased to announce ... help new mothers adjust to their newborn baby and return ... available to all new and in-force short term disability plans ... have access to Newborn and Parenting Resources once their baby ...
... Internationally recognised refractive ... talk the audience through each step of the procedure as the laser treatment is being ... ... procedure in a free live broadcast. He will talk the audience through each step of ...
... ... ... HEALTHeCAREERS , North America’s premier healthcare Network, is advertising more than 14,000 job ... to be one of the few bright spots in the North American job market. ...
... Vivacare.com ... honor of Epilepsy Awareness Month. , ... Berkeley, CA (PRWEB) Nov 9, 2009 -- Vivacare provides ... in honor of Epilepsy Awareness Month. , , , , ,Leading neurologists, such as ...
Cached Medicine News:Health News:CHI's Molecular Medicine Tri-Conference Keynote John Crowley Inspires Feature Film Starring Harrison Ford 2Health News:CHI's Molecular Medicine Tri-Conference Keynote John Crowley Inspires Feature Film Starring Harrison Ford 3Health News:WellPoint's Affiliated Life and Disability Companies Offer Newborn and Parenting Resources to Ease New Mothers' Transition Back to Work After Maternity Leave 2Health News:Eye Surgeon Broadcasts own Surgery 2Health News:Healthcare Web Site Boasts Thousands of Jobs in a Down Economy 2Health News:Neurologists Receive New Patient Education Resources from Vivacare for Epilepsy Awareness Month 2
Proven and Efficient Stand-Alone Device. Offers a choice between alternate breath and every breath delivery. This model provides alternate breath delivery....
... An All-In-One Conserver., ,Offers an average 5:1 ... ,Allows the use of a standard cannula. ... and lightweight cylinders offers ambulatory oxygen patients a ... backed by a 2-year warranty. ...
... ,Offers an average 5:1 increase in usage ... use of a standard cannula. , ,The ... offers ambulatory oxygen patients a superior alternative to ... 2-year warranty. , ...
... Conserver., ,Offers an average 5:1 increase in ... the use of a standard cannula. , ... cylinders offers ambulatory oxygen patients a superior alternative ... a 2-year warranty. , ...
Medicine Products: